Antimicrobial therapies for chronic pain (part 1): analgesic mechanisms

키워드

참고문헌 (179)

1. Cohen SP, "Chronic pain and infection : mechanisms, causes, conditions, treatments, and controversies", BMJ Med, 1, pp.e000108~ (2022)
2. Brizzi KT, "Peripheral nervous system manifestations of infectious diseases", Neurohospitalist, 4, pp.230~240 (2014)
3. Kramer S, "Somatosensory profiles in acute herpes zoster and predictors of postherpetic neuralgia", Pain, 160, pp.882~894 (2019)
4. Gilligan CJ, "Chronic low back pain, bacterial infection and treatment with antibiotics", Spine J, 21, pp.903~914 (2021)
5. Cai Z, "Co-pathogens in periodontitis and inflammatory bowel disease", Front Med(Lausanne), 8, pp.723719~ (2021)
6. Minerbi A, "Gut microbiome in anesthesiology and pain medicine", Anesthesiology, 137, pp.93~108 (2022)
7. Song JH, "Introduction : the goals of antimicrobial therapy", Int J Infect Dis, 7(Suppl 1), pp.S1~S4 (2003)
8. Gilbert DN, "The sanford guide to antimicrobial therapy 2022" (2022), Antimicrobial Therapy, Inc
9. Crockett MT, "Modic type 1 vertebral endplate changes: injury, inflammation, or infection?", AJR Am J Roentgenol, 209, pp.167~170 (2017)
10. Albert HB, "Does nuclear tissue infected with bacteria following disc herniations lead to Modic changes in the adjacent vertebrae?", Eur Spine J, 22, pp.690~696 (2013)
11. Albert HB, "Antibiotic treatment in patients with chronic low back pain and vertebral bone edema(Modic type 1 changes) : a double-blind randomized clinical controlled trial of efficacy", Eur Spine J, 22, pp.697~707 (2013)
12. Bråten LCH, "Efficacy of antibiotic treatment in patients with chronic low back pain and Modic changes (the AIM study): double blind, randomised, placebo controlled, multicentre trial", BMJ, 367, pp.l5654~ (2019)
13. Ford AC, "Systematic review with meta-analysis : the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome", Aliment Pharmacol Ther, 48, pp.1044~1060 (2018)
14. Norton C, "Systematic review : interventions for abdominal pain management in inflammatory bowel disease", Aliment Pharmacol Ther, 46, pp.115~125 (2017)
15. Castiglione F, "Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease", Aliment Pharmacol Ther, 18, pp.1107~1112 (2003)
16. Anothaisintawee T, "Management of chronic prostatitis", chronic pelvic pain syndrome : a systematic review and network metaanalysis, 2011, pp.305, 78~86
17. Du LJ, "Helicobacter pylori eradication therapy for functional dyspepsia : systematic review and meta-analysis", World J Gastroenterol, 22, pp.3486~3495 (2016)
18. Tan VP, "Randomised clinical trial : rifaximin versus placebo for the treatment of functional dyspepsia", Aliment Pharmacol Ther, 45, pp.767~776 (2017)
19. Ford AC, "Functional dyspepsia", Lancet, 396, pp.1689~1702 (2020)
20. Sugano K, "Kyoto global consensus report on Helicobacter pylori gastritis", Gut, 64, pp.1353~1367 (2015)
21. "NCI dictionary of cancer terms" (2011)[URL]
22. Bennett JE, "Douglas, and Bennett’s principles and practice of infectious diseases", pp.278~292 (2015), Saunders
23. Bui T, "StatPearls" (2023), StatPearls Publishing
24. Rothstein JD, "Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression", Nature, 433, pp.73~77 (2005)
25. Hu Y, "An anti-nociceptive role for ceftriaxone in chronic neuropathic pain in rats", Pain, 148, pp.284~301 (2010)
26. Hajhashemi V, "Antiallodynia and antihyperalgesia effects of ceftriaxone in treatment of chronic neuropathic pain in rats", Acta Neuropsychiatr, 25, pp.27~32 (2013)
27. Amin B, "Antinociceptive evaluation of ceftriaxone and minocycline alone and in combination in a neuropathic pain model in rat", Neuroscience, 224, pp.15~25 (2012)
28. Chu K, "Pharmacological induction of ischemic tolerance by glutamate transporter-1(EAAT2)upregulation", Stroke, 38, pp.177~182 (2007)
29. Mohan A, "Minocycline and cephalexin in a patient with spastic neuropathic pain secondary to neurosarcoidosis", Pain Med, 22, pp.2767~2779 (2021)
30. Macaluso A, "Analgesic effect of a single preoperative dose of the antibiotic ceftriaxone in humans", J Pain, 14, pp.604~612 (2013)
31. Rao PS, "Effects of ampicillin, cefazolin and cefoperazone treatments on GLT-1 expressions in the mesocorticolimbic system and ethanol intake in alcohol-preferring rats", Neuroscience, 295, pp.164~174 (2015)
32. Loustaud-Ratti V, "Ribavirin : past, present and future", World J Hepatol, 8, pp.123~130 (2016)
33. Dixit NM, "The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus", Cell Mol Life Sci, 63, pp.832~842 (2006)
34. Abdel-Salam OM, "Antinociceptive and behavioral effects of ribavirin in mice", Pharmacol Biochem Behav, 83, pp.230~238 (2006)
35. Milicevic I, "Ribavirin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats", J Neurosci Res, 72, pp.268~278 (2003)
36. Lavrnja I, "The effect of ribavirin on reactive astrogliosis in experimental autoimmune encephalomyelitis", J Pharmacol Sci, 119, pp.221~232 (2012)
37. Liao SH, "Ribavirin attenuates the respiratory immune responses to influenza viral infection in mice", Arch Virol, 162, pp.1661~1669 (2017)
38. Romeo-Guitart D, "NeuroHeal treatment alleviates neuropathic pain and enhances sensory axon regeneration", Cells, 9, pp.808~ (2020)
39. Fanouriakis A, "2019 update of the EULAR recommendations for the management of systemic lupus erythematosus", Ann Rheum Dis, 78, pp.736~745 (2019)
40. Rempenault C, "Clinical and structural efficacy of hydroxychloroquine in rheumatoid arthritis : a systematic review", Arthritis Care Res (Hoboken), 72, pp.36~40 (2020)
41. Smolen JS, "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2022 update", Ann Rheum Dis, 82, pp.3~18 (2023)[DOI]
42. Srinivasa A, "Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand-related issue?", J Rheumatol, 44, pp.398~ (2017)
43. Khosa S, "Hydroxychloroquine-induced autophagic vacuolar myopathy with mitochondrial abnormalities", Neuropathology, 38, pp.646~652 (2018)
44. Jorge A, "Hydroxychloroquine retinopathy-implications of research advances for rheumatology care", Nat Rev Rheumatol, 14, pp.693~703 (2018)
45. Mauthe M, "Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion", Autophagy, 14, pp.1435~1455 (2018)
46. Kuznik A, "Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines", J Immunol, 186, pp.4794~4804 (2011)
47. Jang CH, "Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes", macrophages by different modes, 2006, pp.45, 703~710
48. Wu SF, "Hydroxychloroquine inhibits CD154 expression in CD4+ T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling", Arthritis Res Ther, 19, pp.183~ (2017)
49. Schrezenmeier E, "Mechanisms of action of hydroxychloroquine and chloroquine : implications for rheumatology", Nat Rev Rheumatol, 16, pp.155~166 (2020)
50. Faraone I, "Recent clinical and preclinical studies of hydroxychloroquine on RNA viruses and chronic diseases : a systematic review", Molecules, 25, pp.5318~ (2020)
51. Chou AK, "Antimalarial primaquine for spinal sensory and motor blockade in rats", J Pharm Pharmacol, 73, pp.1513~1519 (2021)
52. Chang YJ, "Chloroquine for prolonged skin analgesia in rats", Neurosci Lett, 735, pp.135233~ (2020)
53. Chang YJ, "Antimalarial primaquine for skin infiltration analgesia in rats", J Pharm Pharmacol, 73, pp.206~211 (2021)
54. Sánchez-Chapula JA, "Blockade of currents by the antimalarial drug chloroquine in feline ventricular myocytes", J Pharmacol Exp Ther, 297, pp.437~445 (2001)
55. Lee W, "Efficacy of hydroxychloroquine in hand osteoarthritis: a randomized, double-blind, placebo-controlled trial", Arthritis Care Res (Hoboken), 70, pp.1320~1325 (2018)
56. Kingsbury SR, "Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis : a randomized trial", Ann Intern Med, 168, pp.385~395 (2018)
57. Ronaldson SJ, "Cost-effectiveness of hydroxychloroquine versus placebo for hand osteoarthritis : economic evaluation of the HERO trial", F1000Res, 10, pp.821~ (2021)
58. Williams HJ, "Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus", J Rheumatol, 21, pp.1457~1462 (1994)
59. Kedor C, "Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands : results of the OA-TREAT study-a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial", RMD Open, 7, pp.e001660~ (2021)
60. Martí-Carvajal A, "Interventions for treating patients with chikungunya virus infectionrelated rheumatic and musculoskeletal disorders : a systematic review", PLoS One, 12, pp.e0179028~ (2017)
61. Rodrigo C, "Treatment of chikungunyaassociated joint pain : a systematic review of controlled clinical trials", Trans R Soc Trop Med Hyg, 116, pp.889~899 (2022)
62. Eisen D, "Hydroxychloroquine sulfate(Plaquenil)improves oral lichen planus : an open trial", J Am Acad Dermatol, 28, pp.609~612 (1993)
63. Yeshurun A, "Hydroxychloroquine sulphate therapy of erosive oral lichen planus", Australas J Dermatol, 60, pp.e109~e112 (2019)
64. Vermeer HAB, "The use of hydroxychloroquine as a systemic treatment in erosive lichen planus of the vulva and vagina", Br J Dermatol, 185, pp.201~203 (2021)
65. Haight ES, "Of mice, microglia, and(wo)men : a case series and mechanistic investigation of hydroxychloroquine for complex regional pain syndrome", Pain Rep, 5, pp.e841~ (2020)
66. Li J, "Rapamycin : one drug, many effects", Cell Metab, 19, pp.373~379 (2014)
67. Laplante M, "mTOR signaling in growth control and disease", Cell, 149, pp.274~293 (2012)
68. Benjamin D, "Rapamycin passes the torch : a new generation of mTOR inhibitors", Nat Rev Drug Discov, 10, pp.868~880 (2011)
69. Gibbons JJ, "Mammalian target of rapamycin : discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth", Semin Oncol, 36(Suppl 3), pp.S3~S17 (2009)
70. Yao JC, "Everolimus for advanced pancreatic neuroendocrine tumors", N Engl J Med, 364, pp.514~523 (2011)
71. Yangyun W, "Everolimus accelerates Erastin and RSL3-induced ferroptosis in renal cell carcinoma", Gene, 809, pp.145992~ (2022)
72. Khan NA, "mTORC1 regulates mitochondrial integrated stress response and mitochondrial myopathy progression", Cell Metab, 26, pp.419~428 (2017)[DOI]
73. Kang J, "Comparison of rapamycin and methylprednisolone for treating inflammatory muscle disease in a murine model of experimental autoimmune myositis", Exp Ther Med, 20, pp.219~226 (2020)
74. Lilleker JB, "Rapamycin for inclusion body myositis : targeting non-inflammatory mechanisms", Rheumatology(Oxford), 58, pp.375~376 (2019)
75. Khaibullina A, "Rapamycin increases fetal hemoglobin and ameliorates the nociception phenotype in sickle cell mice", Blood Cells Mol Dis, 55, pp.363~372 (2015)
76. Busquets-Garcia A, "Targeting the endocannabinoid system in the treatment of fragile X syndrome", Nat Med, 19, pp.603~607 (2013)
77. Waldner M, "New perspectives on mTOR inhibitors(rapamycin, rapalogs and TORKinibs)in transplantation", Br J Clin Pharmacol, 82, pp.1158~1170 (2016)
78. Wilkinson JE, "Rapamycin slows aging in mice", Aging Cell, 11, pp.675~682 (2012)
79. Schreiber KH, "A novel rapamycin analog is highly selective for mTORC1 in vivo", Nat Commun, 10, pp.3194~ (2019)
80. Lv J, "Effects of intrathecal injection of rapamycin on pain threshold and spinal cord glial activation in rats with neuropathic pain", Neurol Res, 37, pp.739~743 (2015)
81. Feng T, "Rapamycin ameliorates neuropathic pain by activating autophagy and inhibiting interleukin-1β in the rat spinal cord", J Huazhong Univ Sci Technolog Med Sci, 34, pp.830~837 (2014)
82. Tateda S, "Rapamycin suppresses microglial activation and reduces the development of neuropathic pain after spinal cord injury", J Orthop Res, 35, pp.93~103 (2017)
83. Zhang X, "Rapamycin alleviates proinflammatory cytokines and nociceptive behavior induced by chemotherapeutic paclitaxel", Neurol Res, 41, pp.52~59 (2019)
84. Kwon M, "Inhibition of mammalian target of rapamycin(mTOR)signaling in the insular cortex alleviates neuropathic pain after peripheral nerve injury", Front Mol Neurosci, 10, pp.79~ (2017)
85. Asante CO, "Mammalian target of rapamycin signaling in the spinal cord is required for neuronal plasticity and behavioral hypersensitivity associated with neuropathy in the rat", J Pain, 11, pp.1356~1367 (2010)
86. Géranton SM, "A rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states", J Neurosci, 29, pp.15017~15027 (2009)
87. Chen WH, "Spinal protein kinase C", extracellular signalregulated kinase signal pathway mediates hyperalgesia priming, 2018, pp.159, 907~918
88. Lyu D, "The mTOR signaling pathway regulates painrelated synaptic plasticity in rat entorhinal-hippocampal pathways", Mol Pain, 9, pp.64~ (2013)
89. Abdelaziz DM, "Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin", Breast Cancer Res Treat, 143, pp.227~237 (2014)
90. Xu JT, "Opioid receptor-triggered spinal mTORC1 activation contributes to morphine tolerance and hyperalgesia", J Clin Invest, 124, pp.592~603 (2014)
91. Lutz BM, "mTOR, a new potential target for chronic pain and opioidinduced tolerance and hyperalgesia", Mol Pain, 11, pp.32~ (2015)
92. Zhang J, "Systemic rapamycin attenuates morphine-induced analgesic tolerance and hyperalgesia in mice", Neurochem Res, 44, pp.465~471 (2019)
93. Shirooie S, "In vitro evaluation of effects of metformin on morphine and methadone tolerance through mammalian target of rapamycin signaling pathway", J Cell Physiol, 234, pp.3058~3066 (2019)
94. Nguyen LS, "Sirolimus and mTOR inhibitors : a review of side effects and specific management in solid organ transplantation", Drug Saf, 42, pp.813~825 (2019)
95. Zhou YQ, "Minocycline as a promising therapeutic strategy for chronic pain", Pharmacol Res, 134, pp.305~310 (2018)
96. Bastos LF, "Characterization of the antinociceptive and antiinflammatory activities of doxycycline and minocycline in different experimental models", Eur J Pharmacol, 576, pp.171~179 (2007)
97. Bastos LF, "A novel non-antibacterial, non-chelating hydroxypyrazoline derivative of minocycline inhibits nociception and oedema in mice", Br J Pharmacol, 155, pp.714~721 (2008)
98. Guasti L, "Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain", Mol Pain, 5, pp.35~ (2009)
99. Li K, "Systemic minocycline differentially influences changes in spinal microglial markers following formalin-induced nociception", J Neuroimmunol, 221, pp.25~31 (2010)
100. Tabassum S, "Minocycline ameliorates chronic unpredictable mild stress-induced neuroinflammation and abnormal mPFC-HIPP oscillations in mice", Mol Neurobiol, 59, pp.6874~6895 (2022)
101. Padi SS, "Minocycline prevents the development of neuropathic pain, but not acute pain : possible anti-inflammatory and antioxidant mechanisms", Eur J Pharmacol, 601, pp.79~87 (2008)
102. Mika J, "Minocycline reduces the injury-induced expression of prodynorphin and pronociceptin in the dorsal root ganglion in a rat model of neuropathic pain", Neuroscience, 165, pp.1420~1428 (2010)
103. Yoon SY, "Minocycline blocks lipopolysaccharide induced hyperalgesia by suppression of microglia but not astrocytes", Neuroscience, 221, pp.214~224 (2012)
104. Sung CS, "Minocycline and fluorocitrate suppress spinal nociceptive signaling in intrathecal IL-1β-induced thermal hyperalgesic rats", Glia, 60, pp.2004~2017 (2012)
105. Mei XP, "Depressing interleukin-1β contributed to the synergistic effects of tramadol and minocycline on spinal nerve ligation-induced neuropathic pain", Neurosignals, 22, pp.30~42 (2014)
106. Saito O, "Spinal glial TLR4-mediated nociception and production of prostaglandin E(2)and TNF", Br J Pharmacol, 160, pp.1754~1764 (2010)
107. Ismail CAN, "Minocycline alleviates nociceptive response through modulating the expression of NR2B subunit of NMDA receptor in spinal cord of rat model of painful diabetic neuropathy", J Diabetes Metab Disord, 20, pp.793~803 (2021)
108. Cibelli M, "Role of interleukin-1beta in postoperative cognitive dysfunction", Ann Neurol, 68, pp.360~368 (2010)
109. Wang HL, "Minocycline attenuates post-operative cognitive impairment in aged mice by inhibiting microglia activation", J Cell Mol Med, 20, pp.1632~1639 (2016)
110. Takazawa T, "Prevention of postoperative cognitive dysfunction by minocycline in elderly patients after total knee arthroplasty : a randomized, double-blind, placebo-controlled clinical trial", Anesthesiology, 138, pp.172~183 (2023)
111. Lin CS, "Chronic intrathecal infusion of minocycline prevents the development of spinal-nerve ligation-induced pain in rats", Reg Anesth Pain Med, 32, pp.209~216 (2007)
112. Taguchi T, "Peripheral and spinal mechanisms of nociception in a rat reserpineinduced pain model", Pain, 156, pp.415~427 (2015)
113. Cata JP, "The effects of thalidomide and minocycline on taxol-induced hyperalgesia in rats", Brain Res, 1229, pp.100~110 (2008)
114. Masocha W, "Paclitaxel-induced hyposensitivity to nociceptive chemical stimulation in mice can be prevented by treatment with minocycline", Sci Rep, 4, pp.6719~ (2014)
115. Ismail CAN, "Minocycline attenuates the development of diabetic neuropathy by modulating DREAM and BDNF protein expression in rat spinal cord", J Diabetes Metab Disord, 18, pp.181~190 (2019)
116. Amorim D, "Minocycline reduces mechanical allodynia and depressive-like behaviour in type-1 diabetes mellitus in the rat", Behav Brain Res, 327, pp.1~10 (2017)
117. Miranda HF, "Antinociceptive interaction of gabapentin with minocycline in murine diabetic neuropathy", Inflammopharmacology, 25, pp.91~97 (2017)
118. Bastos LF, "Sex-independent suppression of experimental inflammatory pain by minocycline in two mouse strains", Neurosci Lett, 553, pp.110~114 (2013)
119. Cho IH, "Systemic administration of minocycline inhibits formalin-induced inflammatory pain in rat", Brain Res, 1072, pp.208~214 (2006)
120. Cho IH, "Minocycline markedly reduces acute visceral nociception via inhibiting neuronal ERK phosphorylation", Mol Pain, 8, pp.13~ (2012)
121. Kannampalli P, "Analgesic effect of minocycline in rat model of inflammation-induced visceral pain", Eur J Pharmacol, 727, pp.87~98 (2014)
122. Zhang G, "Hippocampal microglial activation and glucocorticoid receptor down-regulation precipitate visceral hypersensitivity induced by colorectal distension in rats", Neuropharmacology, 102, pp.295~303 (2016)
123. Abu-Ghefreh AA, "Enhancement of antinociception by coadministration of minocycline and a non-steroidal anti-inflammatory drug indomethacin in naïve mice and murine models of LPS-induced thermal hyperalgesia and monoarthritis", BMC Musculoskelet Disord, 11, pp.276~ (2010)
124. Song ZP, "Minocycline attenuates bone cancer pain in rats by inhibiting NF-κB in spinal astrocytes", Acta Pharmacol Sin, 37, pp.753~762 (2016)
125. Bu H, "Spinal IFN-γ-induced protein-10(CXCL10)mediates metastatic breast cancer-induced bone pain by activation of microglia in rat models", Breast Cancer Res Treat, 143, pp.255~263 (2014)
126. Burke NN, "Minocycline modulates neuropathic pain behaviour and cortical M1-M2 microglial gene expression in a rat model of depression", Brain Behav Immun, 42, pp.147~156 (2014)
127. Gajbhiye S, "Evaluation of antidepressant effect of minocycline in alcohol abstinenceinduced depression model in mice", Cureus, 14, pp.e28711~ (2022)
128. Sumitani M, "Minocycline does not decrease intensity of neuropathic pain intensity, but does improve its affective dimension", J Pain Palliat Care Pharmacother, 30, pp.31~35 (2016)
129. Habibi-Asl B, "Central administration of minocycline and riluzole prevents morphine-induced tolerance in rats", Anesth Analg, 109, pp.936~942 (2009)
130. Mika J, "Attenuation of morphine tolerance by minocycline and pentoxifylline in naive and neuropathic mice", Brain Behav Immun, 23, pp.75~84 (2009)
131. Shin DA, "Minocycline for controlling neuropathic pain : a systematic narrative review of studies in humans", J Pain Res, 14, pp.139~145 (2021)
132. Pachman DR, "A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy : ACCRU study RU221408I", Support Care Cancer, 25, pp.3407~3416 (2017)
133. Wang XS, "Minocycline for symptom reduction during oxaliplatin-based chemotherapy for colorectal cancer : a phase II randomized clinical trial", J Pain Symptom Manage, 58, pp.662~671 (2019)
134. Wang XS, "Minocycline reduces chemoradiation-related symptom burden in patients with non-small cell lung cancer : a phase 2 randomized trial", Int J Radiat Oncol Biol Phys, 106, pp.100~107 (2020)
135. Martinez V, "The efficacy of a glial inhibitor, minocycline, for preventing persistent pain after lumbar discectomy : a randomized, double-blind, controlled study", Pain, 154, pp.1197~1203 (2013)
136. Vanelderen P, "Effect of minocycline on lumbar radicular neuropathic pain : a randomized, placebo-controlled, double-blind clinical trial with amitriptyline as a comparator", Anesthesiology, 122, pp.399~406 (2015)
137. Syngle A, "Minocycline improves peripheral and autonomic neuropathy in type 2 diabetes : MIND study", Neurol Sci, 35, pp.1067~1073 (2014)
138. Narang T, "Minocycline in leprosy patients with recent onset clinical nerve function impairment", Dermatol Ther (2017)[DOI]
139. Curtin CM, "A doubleblind placebo randomized controlled trial of minocycline to reduce pain after carpal tunnel and trigger finger release", J Hand Surg Am, 42, pp.166~174 (2017)
140. Martins AM, "A review of systemic minocycline side effects and topical minocycline as a safer alternative for treating acne and rosacea", Antibiotics (Basel), 10, pp.757~ (2021)
141. Wozel G, "Dapsone in dermatology and beyond", Arch Dermatol Res, 306, pp.103~124 (2014)
142. Wolf R, "Dapsone", Dermatol Online J, 8, pp.2~ (2002)
143. Khalilzadeh M, "A comprehensive insight into the anti-inflammatory properties of dapsone", Naunyn Schmiedebergs Arch Pharmacol, 395, pp.1509~1523 (2022)
144. Suda T, "Dapsone suppresses human neutrophil superoxide production and elastase release in a calcium-dependent manner", Br J Dermatol, 152, pp.887~895 (2005)
145. Ruzicka T, "Inhibition of rat mast cell arachidonic acid cyclooxygenase by dapsone", J Allergy Clin Immunol, 72, pp.365~370 (1983)
146. Kanoh S, "Dapsone inhibits IL-8 secretion from human bronchial epithelial cells stimulated with lipopolysaccharide and resolves airway inflammation in the ferret", Chest, 140, pp.980~990 (2011)
147. Abe M, "A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factoralpha production from activated mononuclear cells on cutaneous lupus erythematosus", Clin Exp Dermatol, 33, pp.759~763 (2008)
148. Rodríguez E, "Dapsone prevents morphological lesions and lipid peroxidation induced by quinolinic acid in rat corpus striatum", Toxicology, 139, pp.111~118 (1999)
149. Santamaría A, "Neuroprotective effect of dapsone against quinolinate-and kainateinduced striatal neurotoxicities in rats", Pharmacol Toxicol, 81, pp.271~275 (1997)
150. Mata-Bermudez A, "Dapsone prevents allodynia and hyperalgesia and decreased oxidative stress after spinal cord injury in rats", Spine (Phila Pa 1976), 46, pp.1287~1294 (2021)
151. Ríos C, "Anti-apoptotic effects of dapsone after spinal cord injury in rats", Neurochem Res, 40, pp.1243~1251 (2015)
152. Diaz-Ruiz A, "Delayed administration of dapsone protects from tissue damage and improves recovery after spinal cord injury", J Neurosci Res, 89, pp.373~380 (2011)
153. Shayesteh S, "Dapsone improves the vincristine-induced neuropathic nociception by modulating neuroinflammation and oxidative stress", Daru, 30, pp.303~310 (2022)
154. Swinson DR, "Double-blind trial of dapsone against placebo in the treatment of rheumatoid arthritis", Ann Rheum Dis, 40, pp.235~239 (1981)
155. Fowler PD, "Report on chloroquine and dapsone in the treatment of rheumatoid arthritis : a 6-month comparative study", Ann Rheum Dis, 43, pp.200~204 (1984)
156. Haar D, "A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis", Scand J Rheumatol, 22, pp.113~118 (1993)
157. Gusdorf L, "Neutrophilic urticarial dermatosis : a review", Ann Dermatol Venereol, 145, pp.735~740 (2018)
158. Shi H, "Treatment of cutaneous lupus erythematosus : current approaches and future strategies", Curr Opin Rheumatol, 32, pp.208~214 (2020)
159. Zampeli E, "Dapsone : an old drug effective for subacute cutaneous lupus erythematosus", Rheumatology (Oxford), 58, pp.920~921 (2019)
160. Ujiie H, "Lupus erythematosus profundus successfully treated with dapsone : review of the literature", Arch Dermatol, 142, pp.399~401 (2006)
161. de Risi-Pugliese T, "Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus : 10 new cases and a literature review of 118 cases", Semin Arthritis Rheum, 48, pp.83~89 (2018)
162. Lu Q, "Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus", J Autoimmun, 123, pp.102707~ (2021)
163. Diaz-Ruiz A, "Dapsone, more than an effective neuro and cytoprotective drug", Curr Neuropharmacol, 20, pp.194~210 (2022)
164. Nader-Kawachi J, "Neuroprotective effect of dapsone in patients with acute ischemic stroke : a pilot study", Neurol Res, 29, pp.331~334 (2007)
165. Lee JH, "The neuroinflammasome in Alzheimer's disease and cerebral stroke", Dement Geriatr Cogn Dis Extra, 11, pp.159~167 (2021)
166. Walling HW, "Cutaneous lupus erythematosus : issues in diagnosis and treatment", Am J Clin Dermatol, 10, pp.365~381 (2009)
167. Ahrens EM, "Dapsone-induced peripheral neuropathy", Int J Dermatol, 25, pp.314~316 (1986)
168. Gutmann L, "Dapsone motor neuropathy--an axonal disease", Neurology, 26(6), pp.514~516 (1976)
169. Prussick R, "Dapsone hypersensitivity syndrome", J Am Acad Dermatol, 35(2), pp.346~349 (1996)
170. Zaccone G, "Expression of the antimicrobial peptide Piscidin 1 and neuropeptides in fish gill and skin : a potential participation in neuro-immune interaction", Mar Drugs, 20, pp.145~ (2022)
171. Lauriano ER, "Neuroepithelial cells (NECs) and mucous cells express a variety of neurotransmitters and neurotransmitter receptors in the gill and respiratory air-sac of the catfish Heteropneustes fossilis (Siluriformes, Heteropneustidae):a possible role in local immune defence", Zoology (Jena), 148, pp.125958~ (2021)
172. Salger SA, "A diverse family of host-defense peptides(Piscidins)exhibit specialized anti-bacterial and antiprotozoal activities in fishes", PLoS One, 11, pp.e0159423~ (2016)
173. Chen WF, "The use of the antimicrobial peptide piscidin(PCD)-1 as a novel anti-nociceptive agent", Biomaterials, 53, pp.1~11 (2015)
174. Cheng MH, "Piscidin-1 induces apoptosis via mitochondrial reactive oxygen species-regulated mitochondrial dysfunction in human osteosarcoma cells", Sci Rep, 10, pp.5045~ (2020)
175. Ting CH, "Targeting FOSB with a cationic antimicrobial peptide, TP4, for treatment of triple-negative breast cancer", Oncotarget, 7, pp.40329~40347 (2016)
176. Ban TA, "The role of serendipity in drug discovery", Dialogues Clin Neurosci, 8, pp.335~344 (2006)
177. Theuretzbacher U, "The global preclinical antibacterial pipeline", Nat Rev Microbiol, 18, pp.275~285 (2020)
178. Mouraux A, "Challenges and opportunities in translational pain research-An opinion paper of the working group on translational pain research of the European pain federation(EFIC)", Eur J Pain, 25, pp.731~756 (2021)
179. Lapolla W, "Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster : open-label study", Arch Dermatol, 147, pp.901~907 (2011)

관련 논문AI추천